HomeMy WebLinkAboutWA ST Health Care Authority HCA Contract K5885DocuSign Envelope lD: 7C237 4F6-A621 -4812-836E-C9F031 F54785
Washington State
Health Care thority
CONTRACT
AMENDMENT
HCA Contrac't No.: K5885
Amendment No.: 02
THIS AM EN D M ENT TO THE CONTRACT between Washi ngton State Caretsthe
whose n am e a ppears below and ts effective as of the date
Health Auth ority and the party
set forth below.
CONTRACTOR NAME
Kittitas County
CONTRACTOR doing business as (DBA)
Kittitas County Sheriff - Jail
CONTRACTOR ADDRESS
205 W. Sth Ave, Ste 1/Jail
Ellensburg, WA 98926
CONTRACTOR CONTRACT MANAGER
Name: Clay Myers
Email: clay. myers@co. kittitas.wa. us
AMENDMENT START DATE
July 1 ,2023
AMENDMENT END DATE
June 30,2024
CONTRACT END DATE
June 30,2024
Prior Maximum Gontract Amount
$523,035.00
Amount of lncrease
$229,740.00
Total Maximum Compensation
$752,775.00
WHEREAS, HCA and Contractor previously entered into a Contract to develop and implement or expand the
MOUD in Jails programs, and;
WHEREAS, HCA and Contractor wish to amend the Contract pursuant to Section 4.3, Amendments to extend
the term, increase funds, and amend the Statement of Work;
Now THEREFORE, the parties agree the contract is amended as foilows:
1. Section 3.2, Term, is amended to extend the end date from June 30, 2023to June 30, 2024.
2. Section 3.3, Compensation, Subsection 3.3.1, is amended to increase the Total Maximum Compensation
by $229,740.00, from $523,035.00 to $752,775.00. All internal references to the Total Maximum
Compensation amount are updated accordingly.
3. Section 3.7, lncorporation of Documents and Order of Precedence is amended to read as follows:
Each of the documents listed below is by this reference incorporated into this Contract. ln the event of an
inconsistency, the inconsistency will be resolved in the following order of precedence:
3.7.1 Applicable Federal and State of Washington statutes and regulations;
3.7.2 Recitals;
3.7.3 Special Terms and Conditions;
3.7.4 General Terms and Conditions;
3.7.5 Attachment 1: Data Use Security and Confidentiality;
3.7.6 Attachment 2: Data Security Requirements;
3.7.7 Attachment 3: HCA Small Numbers Standards;
HCA Contract No. K5885-02 Page I of7
DocuSign Envelope lD: 7 C237 4F6-A621 -4812-836E-C9F031 F54785
3.7.8 Attachment 4: Certificate of Destruction;
3.7.9 Schedule A: Statement of Work;
3.7.'lO Schedule A-1: Statement of Work (July 1 ,2022-June 30, 2OZ3);
3.7.1'l Schedule A-2: Statement of Work (July 1, 2023-June 30,2O24):
3.7.12 Exhibit A: HCA RFA #2021HCA42 for Medication for Opioid Use Disorder (MOUD) in Jails
Program, dated December 29,2021;
3.7.13 Exhibit B: Contractor's Response dated January 20,2022; and
3.7.14 Any other provision, term or material incorporated herein by reference or otherwise incorporated
4. Schedule A-2, Statement of Work, effective July 1 ,2023 through June 30, 2024 is attached hereto and
incorporated herein.
5. This Amendment will be effective July 1 , Z0Zg ("Effective Date').
6. All capitalized terms not otherwise defined herein have the meaning ascribed to them in the Contract.
7. All other terms and conditions of the Contract remain unchanged and in full force and effect.
The parties signing below warrant that they have read and understand this Amendment and have authority to
execute the Amendment. This Amendment will be binding on HCA only upon signature by both parties.
CONTRACTOR
-[t"*"^;- l*o.^l^*
PRINTED NAME AND TITLE
4/4'l /rYeks, sl/EAu>F
DATE SIGNED
9-e -4t
PRINTEP.MME AND TITLEAnona Howenon
Deputy Contracts Administri
DATE SIGNED
8t16t2023
tor
HCA Contract No. K5885-02 Page 2 of7
DocuSign Envef ope lD'. 7 C237 4F6-A62'l -4812-836E-CgF03'l F54785
Schedule A-2: Statement of Work
July 1, 2023-June 30, 2024
1. Purpose.
To provide medication for opioid use disorder (MOUD) in jails to incarcerated individuals who are
identified with an opioid use disorder (OUD). To support a full MOUD program which includes the
following: an OUD screening, discussion of MOUD options between the incarcerated individual and
provider, initiation prior to the onset of withdrawal or continuation of MOUD, release and reentry planning
to include connection with continued treatment, same day release appointment when possible or MOUD
to bridge patient until next appointment and naloxone upon release. Reentry planning may also include
assisting the incarcerated individualwith sign-up of Medicaid, reestablishing Medicaid and connection
with the Managed Care Organizations (MCOs).
Health Equity - This project also intends to address inequities in OUD treatment and recovery services by
providing medically necessary treatment for opioid use disorderto incarcerated individuals. MOUD in jaili
programs should understand cultural barriers and provide culturally appropriate services and recognize
the need for inclusion of people with lived experiences in the development of the MOUD in jails programs.
Additionally, this project intends to identify stigma and educate staff to ensure ongoing colliboration and
openness to change.
2. Performance Work Statement.
The Contractor shall ensure funds are responsibly used towards the MOUD program in the jail/jails and
provide the standard of care core components which include:
a. FDA approved medication for opioid use disorder (MOUD) must be available and offered to all
incarcerated individuals who are identified with OUD at intake. lndividuals with OUD may decline
MOUD at any time, but ongoing discussions on MOUD may be offered.
b. Methadone, buprenorphine, naltrexone should all be offered unless: (a) an opioid treatment
program (OTP) is not within reasonable driving distance from the jail, in which case the jail is not
required to offer methadone as an option; or (b) there is no available buprenorphine provider in
the community to which the patient will likely release, in which case the jail is not required to offer
buprenorphine as an option. Naltrexone may be provided in oralformulation while the patient is
incarcerated, but injectable long-acting naltrexone must be offered as an option prior to release.
Long-acting injectable buprenorphine can also be offered.
c.MOUD must be continued for those who are already taking MOUD upon entering the facility.
MOUD is continued using the same medication, at the same dose unless ordered otherwise by
the prescriber based on clinical need (documented in the patient's medical record) with the
exception of injectable long-acting naltrexone which may be converted to an equivalent oral dose
until just prior to release and the injectable form is restarted. Methadone may be transitioned to
buprenorphine if the jail is not a licensed opioid treatment program (OTP) and the nearest OTp is
not within reasonable driving distance from the jail. The presence of other illicit or controlled
substances should not result in discontinuation of MOUD (consistent with the 2O2O ASAM
National Practice Guideline for the Treatment of Opioid lJse Disordef) Please also review and
impfement the newly released (June 2023), Bureau of Justice Assistance , Guidelines for
Managinq Substance Withdrawal in Jails .
d. Screening for risk of acute withdrawal must be done upon intake. Screening for opioid use
disorder (OUD) absent a risk of acute withdrawal must also be done, but it may be done after
HCA Contract No. K5885-02 Page 3 of 7
Docu S ig n Envelope lD: 7 C237 4F 6-A621 -481 2-836E-Cg F03 1 F54785
intake, as long as the delay does not impair the ability to begin treatment prior to release. The
incarcerated individual must be educated on treatment choices and the process for continuation
of access to MOUD, during incarceration, and upon release. (See resources for vatidated tool
suggestions.)
Individuals entering the facility who are physically dependent on opioids, must be offered MOUD
treatment; withdrawal (including withdrawal using buprenorphine or methadone) is not
acceptable unless the patient provides an informed refusal of treatment or the patient elects
MOUD treatment with naltrexone, in which case withdrawal is clinically required. Use of other
medications (clonidine, anti-emetics, anti-diarrheals, analgesics) may be used as adjuncts or
may be used in place of opioid agonist or partial agonist if the individual so chooses, but they
may not be the only withdrawaltreatment available.
f Methadone and buprenorphine must be administered daily or more frequently. Alternate-day
("Balloon") dosing of buprenorphine may be used in rare cases based on a clinical need, the
decision for which is arrived at jointly between the healthcare provider and patient and is well-
documented in the patient's medical record.
g' Release planning and reentry coordination completed as soon as possible to ensure an effective
plan is in place prior to release or in the event of an unexpected release of an incarcerated
individualwho needs continued treatment and services.
h. Provide at least 2 doses of naloxone and naloxone administration training to all incarcerated
individuals with OUD upon release.
i, schedule the first community appointment with a treatment facility
Provide - in hand upon release and at no cost to the individual - sufficient doses of MOUD to
bridge patient until scheduled MOUD follow-up appointment at community treatment facility
(does not apply to patients treated with injectable MOUD).
lndividuals who are at risk of being released directly from court are informed, prior to going
to court, that they may request to be transported back to the jail by staff to receive these
medications prior to going home.
[.ln situations where an appointment cannot be made, e.g., after-hours bail-out, resident is
given enough medication to last until the next available appointment at the community
treatment facility. lf that date is unknown, the individual is given a minimum ol a7-day
supply.
iii. ln situations where medications cannot be provided upon release, e.g., unscheduled
release at a time when medical staff are not present in the jail, the individual is informed
that he/she may either return to the jail in the morning to receive bridge medications or, if
no medical staff are present the following day, will have a prescription for the same
bridging medication called to a local pharmacy, at no cost to the individual.
k. Ensure policies and procedures are in place to mitigate medication diversion.
3. Allowable Expenses.
e
HCA Contract No. K5885-02 Page 4 of7
DocuSign Envef ope lD: 7 C237 4F6-A621 -48'12-B,36E-C9F03'1 FS4785
The needs of county, city and tribaljails to develop or sustain an MOUD program are prioritized,
and this funding is designated for those efforts. This is not an exhaustive list. The monthly
progress report should detailwhat the funds are being spent on. Anything not on this list needs
written approval, (email HCA contract manager).
i. MOUD program staffing FTEs which may include:
1. Nursing
2. Medical assistants
3. Providers, prescribers
4. Correctionalstaff
5. Clerical or administrative staff for MOUD program reporting and administration6. Care navigators, reentry coordinators, peer support, substance use disorder
professionals.
ii. Medications for opioid use disorder (MOUD) FDA approved buprenorphine, (this can
include long-acting injectable buprenorphine), methadone and naltrexone.
iii. Naloxone for jail and staff.
iv. Technology which would support the MOUD program.
1. Tablets, phones, security, interneUwifi enhancements to allow for telehealth, etc.
v. MOUD staff supplies
1. Desk, chair, computer, phone, etc.
vi. Transportation for program participants upon release to first appointment, pick up
prescription, safe place, etc.
vii. Release kit items such as:
1. Naloxone
2. Gift cards
3. Clothing, shoes
4. Personal hygiene items5. Phones
b. Kittitas County Jailwill continue the MOUD program. The improvements made will allow for staff
to be more effective in improving the standard of care and implementation of the core components
of this contract.
4. Data Collection.
a. Participation requires performance monitoring activities, including timely and accurate data
reporting to the Health Care Authority, Division of Behavioral Health, and Recovery (HCA DBHR).
Further evaluation, including on- and off-site data collection may be conducted by HCn OAHn or
a third-party.
b. The contractor willsubmit a monthly report, template provided by HCA DBHR, by the 1oth day of
the month with the following participant information, (identified as having a current OUD), tor ine
previous month:
i. Fullname
a
HCA Gontract No. K5885-02 Page 5 of7
DocuSign Envelope lD'. 7 C237 4F6-A621 -4812-836E-C9F031 F54785
ii. Date of birth
iii. Provider One #, SSN or another unique identifier
iv. Date of booking
v. Date MOUD started: continued or induction?
vi. Date of release if applicable
vii. Schedule first MOUD appointment upon release
viii. Which MOUD provided upon release
c. lnformation will be collected via the Managed File Transfer (MFT). lt may be shared with
Research Data and Analysis (RDA) for evaluation purposes.
5. Contract ManagemenUAccounting.
a. Ensure specific tools, such as job descriptions, policies and procedures, and statements of work,
are developed, and staff are adequately trained on these tools, to ensure consistent and
appropriate practice.
b. Attend required monthly meetings with HCA DBHR program administrator to discuss project
contract requirements, compliance, problem-solving and attend trainings. Attend additional
meetings as required or deemed necessary by the HCA DBHR program administrator.
c. Contractor will cooperate with periodic site visits by the HCA DBHR program administrator or
designee and make all relevant records and personnel available.
d. Submit a monthly report and a data spreadsheet through the Managed File Transfer portal (MFT)
as detailed in the deliverables table with the A-19 invoice.
FY2024 Gontract Deliverables Table
Activitv Description Due Date Payment
Monthly
progress
reports
Report must include how funding is
being spent, status of hiring staff, status
of MOUD purchases and other
supplies. Program details and how the
standard of care, core components
(Section 2) are being met, baniers and
successes, technical assistance and
training participation, staff changes and
additional information as needed.
Monthly:
Reports due on
the 1Oth of every
month beginning
with August 10,
2023.
$114,870.00
($9,572.50 x 12)
Monthly
Data
Collection
spreadsheet
Data spreadsheet filled out completely
with section 4.b. above following
template provided by HCA and shared
via MFT.
Monthly:
Due on the 1Oth
of every month
beginning with
August 10,2023.
$114,870.00
($9,572.50 x 12)
Amendment Total $229,740.00
6. Billing and Payment.
a. This amendment total is for $229,740.00.
b. lnvoice System. The Contractor shall submit invoices using State Form A-19 lnvoice Voucher, or
such other form as designated by HCA. Consideration for services rendered shall be payable
HCA Contract No. K5885-02 Page 6 of 7
DocuSign Envelope lD: 7 C237 4F 6-A621 -48'12-B,36E-C9F031 F54785
c.
upon receipt of properly completed invoices which shall be submitted to the program
administrator, Rachel Meade, via MFT by the Contractor monthly. Payments shall be in
accordance with delivery and approval of deliverables as outlined in the Deliverables Table.
Payment. Payment shall be considered timely if made by HCA within thirty (30) days after receipt
and acceptance by HCA of the properly completed invoices. Payment shall be sent to the
address designated by the Contractor on page one (1) of this Contract. HCA may, at its sole
discretion, withhold payment claimed by the Contractor for services rendered if Contractor fails to
satisfactorily comply with any term or condition of this Contract.
d. Claims for payment submitted by the Contractor to HCA for amounts due and payable under this
agreement that were incurred prior to the expiration date shall be paid by HCA if received by
HCA within 90 days after the expiration date.
e. HCA shall not reimburse the Contractor for any fees and expenses which exceed the maximum
consideration of this contract.
HCA Contract No. K5885-02 Page 7 of7